Format

Send to

Choose Destination
Sci Rep. 2017 Sep 29;7(1):12408. doi: 10.1038/s41598-017-12572-4.

The identification of molecular target of (20S) ginsenoside Rh2 for its anti-cancer activity.

Author information

1
Key Laboratory for Molecular Enzymology and Engineering, the Ministry of Education, College of Life Science, Jilin University, Changchun, Jilin, 130012, China.
2
College of Chemistry, Jilin University, Changchun, 130012, Jilin, China.
3
Key Laboratory for Molecular Enzymology and Engineering, the Ministry of Education, College of Life Science, Jilin University, Changchun, Jilin, 130012, China. yhjin@jlu.edu.cn.

Abstract

The 20S ginsenoside Rh2 (G-Rh2) effectively inhibits cancer cell growth and survival in both animal models and cell lines. However, its molecular targets and mechanism of action remain largely unknown. By screening for molecules that interact with (20S)G-Rh2 in a phage display assay, we have identified Annexin A2 as a potential target that mediates its anti-cancer activity. Isothermal titration calorimetry and a cellular thermal shift assay demonstrated that (20S)G-Rh2 directly bound to either recombinant or intracellular Annexin A2. This binding inhibited the interaction between Annexin A2 and the NF-кB p50 subunit, which attenuated the nuclear translocations of NF-кB p50 subunit and reduced the transactivation activity of NF-кB. Correspond to this result, (20S)G-Rh2 treatment significantly down-regulated the expression of IAPs (inhibitors of apoptosis), the well-established NF-кB targets that promote cell survival. Moreover, (20S)G-Rh2 synergized with Annexin A2 inactivation to promote apoptosis. Taken together, this study for the first time suggests a cellular target and a molecular pathway by which (20S)G-Rh2 inhibits cancer cell growth. As over-expression of Annexin A2 was evident in human hepatoma, (20S)G-Rh2 might be a promising natural compound for targeted liver cancer therapy.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center